Evidence map›Paper›PMID 39962461›Full record

ArticleBMC cancer2025

Integrated analysis of single-cell and bulk transcriptomics reveals cellular subtypes and molecular features associated with osteosarcoma prognosis.

Feng Liu, Tingting Zhang, Yongqiang Yang, Kailun Wang, Jinlan Wei, Ji-Hua Shi, Dong Zhang, Xia Sheng, Yi Zhang, Jing Zhou and 1 more

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Feng Liu *Department of Hand/Foot/Ankle Surgery, Qujing Affiliated Hospital of Kunming Medical University, Qujing, 655099, China.
Tingting Zhang *School of Life and Health Sciences, Hainan University, Haikou, 570228, China.
Yongqiang Yang *Department of Hand/Foot/Ankle Surgery, Qujing Affiliated Hospital of Kunming Medical University, Qujing, 655099, China.
Kailun WangSchool of Life and Health Sciences, Hainan University, Haikou, 570228, China.
Jinlan WeiSchool of Life and Health Sciences, Hainan University, Haikou, 570228, China.
Ji-Hua ShiDepartment of Orthopaedic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Dong ZhangDepartment of Breast and Thyroid Surgery, Shandong Provincial Hospital, Shandong First Medical University, Jinan, 250021, China.
Xia ShengDepartment of Hand/Foot/Ankle Surgery, Qujing Affiliated Hospital of Kunming Medical University, Qujing, 655099, China.
Yi ZhangDepartment of Orthopaedic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. zhangyi@zzu.edu.cn.
Jing ZhouDepartment of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. jzhou_whuh@foxmail.com.
Faming ZhaoSchool of Life and Health Sciences, Hainan University, Haikou, 570228, China. famingzhao@foxmail.com.

Funding

National Key R&D Program of China 2022YFA0807000Yunnan Provincial Department of Science and Technology Kunming Medical Joint Special General Project 202201AY070001-218Yunnan Science and Technology Talent and Platform Program 202205AF150054
6 · The paper itself

Abstract

backgroundOsteosarcoma (OS) is the most common primary bone malignancy with variable molecular biology and prognosis. However, our understanding of the association between cell types and OS progression remains poor.

methodsWe generated a human OS cell atlas by integrating over 110,000 single cells from 17 samples. Multiple machine learning algorithms were applied to develop tumor purity prediction models based on transcriptomic profile of OS. The Scissor algorithm and gene enrichment analyses were conducted to delve into cell-intrinsic molecular characteristics linked to OS prognosis. Moreover, the study investigated the impact of ATF6α in OS aggressiveness through genetic and pharmacological loss of function analyses. Lastly, the CellChat algorithm was employed to investigate cell-cell communications.

resultsUtilizing the high-quality human OS cell atlas, we identified tumor purity as a prognostic indicator and developed a robust tumor purity prediction model. We respectively delineated cancer cell- and immune cell-intrinsic molecular characteristics associated with OS prognosis at single-cell resolution. Interestingly, tumor cells with activated unfolded protein response (UPR) pathway were significantly associated with disease aggressiveness. Notably, ATF6α emerged as the top-activated transcription factor for this tumor subcluster. Subsequently, we confirmed that ATF6α was markedly associated with OS progression, while both genetic and pharmacological inhibition of ATF6α impaired the survival of HOS cells. Lastly, we depicted the landscape of signal crosstalk between the UPR-related subcluster and other cell types within the tumor microenvironment.

conclusionIn summary, our work provides novel insights into the molecular biology of OS, and offers valuable resource for OS biomarker discovery and treatment strategy development.

Indexed as

Bone NeoplasmsOsteosarcomaSingle-Cell AnalysisTranscriptomeActivating Transcription Factor 6Biomarkers, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMachine LearningPrognosisTumor MicroenvironmentUnfolded Protein ResponseActivating Transcription Factor 6ATF6 protein, humanBiomarkers, TumorATF6αOsteosarcomaPrognosisSingle-cell RNA-seqUnfolded protein response

Identifiers

PMID39962461
PMCPMC11834279

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.